It's reported that 76 per cent of the 28 involved in a Phase Two trial undertaken in Colorado didn't meet the clinical diagnostic criteria of PTSD 12 months on from receiving treatment.
Treatment consisted of a pair of two day-long MDMA-led sessions with integrative therapy sessions. A third MDMA treatment session was also held.
The Multidisciplinary Association for Psychedelic Studies (MAPS) are carrying out the trials. Phase Three kicked off in September this year, involving between 200 and 300 people in the United States, Canada and Israel. These are expected to go on for two years.
[Via: New Atlas]
[Photo: MDMA Team]
Dave Turner is Mixmag's Digital News Editor, follow him on Twitter